Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer

---

Copy For Citation

TAŞKIN S., GÜNGÖR M., Ortac F., Oztuna D.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.288, no.6, pp.1399-1403, 2013 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 288 Issue: 6
• Publication Date: 2013
• Doi Number: 10.1007/s00404-013-2924-7
• Journal Name: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.1399-1403
• Keywords: Neoadjuvant chemotherapy, Ovarian cancer, Optimal cytoreduction, Survival, CARCINOMA, DEBULKING, DISEASE
• Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance